FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114058467> ?p ?o ?g. }

• W2114058467 abstract "Tamoxifen is an effective treatment for breast cancer but an undesirable side-effect is an increased risk of endometrial cancer, particularly rare tumor types associated with poor prognosis. We investigated whether tamoxifen therapy increases mortality among breast cancer patients subsequently diagnosed with endometrial cancer. We pooled case-patient data from the three largest case-control studies of tamoxifen in relation to endometrial cancer after breast cancer (1,875 patients: Netherlands, 765; United Kingdom, 786; United States, 324) and collected follow-up information on vital status. Breast cancers were diagnosed in 1972 to 2005 with endometrial cancers diagnosed in 1978 to 2006. We used Cox proportional hazards survival analysis to estimate hazard ratios (HRs) and 95% confidence intervals (CI). A total of 1,104 deaths occurred during, on average, 5.8 years following endometrial cancer (32% attributed to breast cancer, 25% to endometrial cancer). Mortality from endometrial cancer increased significantly with unfavorable non-endometrioid morphologies (P < 0.0001), International Federation of Gynaecology and Obstetrics staging system for gynecological malignancy (FIGO) stage (P < 0.0001) and age (P < 0.0001). No overall association was observed between tamoxifen treatment and endometrial cancer mortality (HR = 1.17 (95% CI: (0.89 to 1.55)). Tamoxifen use for at least five years was associated with increased endometrial cancer mortality (HR = 1.59 (1.13 to 2.25)). This association appeared to be due primarily to the excess of unfavorable histologies and advanced stage in women using tamoxifen for five or more years since the association with mortality was no longer significant after adjustment for morphological type and FIGO stage (HR = 1.37 (0.97 to 1.93)). Those patients with endometrioid tumors, who stopped tamoxifen use at least five years before their endometrial cancer diagnosis, had a greater mortality risk from endometrial cancer than endometrioid patients with no tamoxifen exposure (HR = 2.11 (1.13 to 3.94)). The explanation for this latter observation is not apparent. Patients with endometrial cancer after breast cancer who received tamoxifen treatment for five years for breast cancer have greater endometrial cancer mortality risk than those who did not receive tamoxifen. This can be attributed to non-endometrioid histological subtypes with poorer prognosis among long term tamoxifen users." @default.
• W2114058467 created "2016-06-24" @default.
• W2114058467 creator A5003474947 @default.
• W2114058467 creator A5003942850 @default.
• W2114058467 creator A5009928901 @default.
• W2114058467 creator A5018908854 @default.
• W2114058467 creator A5024696344 @default.
• W2114058467 creator A5028614473 @default.
• W2114058467 creator A5030601121 @default.
• W2114058467 creator A5058453547 @default.
• W2114058467 creator A5079827557 @default.
• W2114058467 date "2012-06-01" @default.
• W2114058467 modified "2023-10-07" @default.
• W2114058467 title "Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries" @default.
• W2114058467 cites W1961026612 @default.
• W2114058467 cites W1970654722 @default.
• W2114058467 cites W1971045560 @default.
• W2114058467 cites W1973503731 @default.
• W2114058467 cites W1974196659 @default.
• W2114058467 cites W1997025193 @default.
• W2114058467 cites W2001416462 @default.
• W2114058467 cites W2004222974 @default.
• W2114058467 cites W2097006862 @default.
• W2114058467 cites W2098544956 @default.
• W2114058467 cites W2112669742 @default.
• W2114058467 cites W2118728607 @default.
• W2114058467 cites W2129241905 @default.
• W2114058467 cites W2146569020 @default.
• W2114058467 cites W2154377786 @default.
• W2114058467 cites W2155481621 @default.
• W2114058467 cites W2157458354 @default.
• W2114058467 cites W2169449395 @default.
• W2114058467 cites W2170976149 @default.
• W2114058467 cites W2258822336 @default.
• W2114058467 cites W2327883626 @default.
• W2114058467 cites W2987227731 @default.
• W2114058467 cites W4231239923 @default.
• W2114058467 doi "https://doi.org/10.1186/bcr3206" @default.
• W2114058467 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3446354" @default.
• W2114058467 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22691381" @default.
• W2114058467 hasPublicationYear "2012" @default.
• W2114058467 type Work @default.
• W2114058467 sameAs 2114058467 @default.
• W2114058467 citedByCount "71" @default.
• W2114058467 countsByYear W21140584672013 @default.
• W2114058467 countsByYear W21140584672014 @default.
• W2114058467 countsByYear W21140584672015 @default.
• W2114058467 countsByYear W21140584672016 @default.
• W2114058467 countsByYear W21140584672017 @default.
• W2114058467 countsByYear W21140584672018 @default.
• W2114058467 countsByYear W21140584672019 @default.
• W2114058467 countsByYear W21140584672020 @default.
• W2114058467 countsByYear W21140584672021 @default.
• W2114058467 countsByYear W21140584672022 @default.
• W2114058467 countsByYear W21140584672023 @default.
• W2114058467 crossrefType "journal-article" @default.
• W2114058467 hasAuthorship W2114058467A5003474947 @default.
• W2114058467 hasAuthorship W2114058467A5003942850 @default.
• W2114058467 hasAuthorship W2114058467A5009928901 @default.
• W2114058467 hasAuthorship W2114058467A5018908854 @default.
• W2114058467 hasAuthorship W2114058467A5024696344 @default.
• W2114058467 hasAuthorship W2114058467A5028614473 @default.
• W2114058467 hasAuthorship W2114058467A5030601121 @default.
• W2114058467 hasAuthorship W2114058467A5058453547 @default.
• W2114058467 hasAuthorship W2114058467A5079827557 @default.
• W2114058467 hasBestOaLocation W21140584671 @default.
• W2114058467 hasConcept C121608353 @default.
• W2114058467 hasConcept C126322002 @default.
• W2114058467 hasConcept C131872663 @default.
• W2114058467 hasConcept C143998085 @default.
• W2114058467 hasConcept C207103383 @default.
• W2114058467 hasConcept C2777088508 @default.
• W2114058467 hasConcept C2777176818 @default.
• W2114058467 hasConcept C2778515176 @default.
• W2114058467 hasConcept C2780140570 @default.
• W2114058467 hasConcept C29456083 @default.
• W2114058467 hasConcept C44249647 @default.
• W2114058467 hasConcept C50382708 @default.
• W2114058467 hasConcept C530470458 @default.
• W2114058467 hasConcept C71924100 @default.
• W2114058467 hasConceptScore W2114058467C121608353 @default.
• W2114058467 hasConceptScore W2114058467C126322002 @default.
• W2114058467 hasConceptScore W2114058467C131872663 @default.
• W2114058467 hasConceptScore W2114058467C143998085 @default.
• W2114058467 hasConceptScore W2114058467C207103383 @default.
• W2114058467 hasConceptScore W2114058467C2777088508 @default.
• W2114058467 hasConceptScore W2114058467C2777176818 @default.
• W2114058467 hasConceptScore W2114058467C2778515176 @default.
• W2114058467 hasConceptScore W2114058467C2780140570 @default.
• W2114058467 hasConceptScore W2114058467C29456083 @default.
• W2114058467 hasConceptScore W2114058467C44249647 @default.
• W2114058467 hasConceptScore W2114058467C50382708 @default.
• W2114058467 hasConceptScore W2114058467C530470458 @default.
• W2114058467 hasConceptScore W2114058467C71924100 @default.
• W2114058467 hasIssue "3" @default.
• W2114058467 hasLocation W21140584671 @default.
• W2114058467 hasLocation W21140584672 @default.
• W2114058467 hasLocation W21140584673 @default.
• W2114058467 hasLocation W21140584674 @default.
• W2114058467 hasLocation W21140584675 @default.

• next